Denali therapeutics announces new interim data from phase 1/2 study of dnl310 (etv:ids) in mps ii (hunter syndrome) at ssiem 2022

South san francisco, calif., aug. 31, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage disorders, today announced new interim results from a phase 1/2 trial of dnl310 (etv:ids) in mps ii (hunter syndrome). dnl310 is an investigational, brain-penetrant enzyme replacement therapy designed to address the cognitive, behavioral, and physical manifestations of hunter syndrome. the data were presented at the 2022 society for the study of inborn errors of metabolism (ssiem) annual symposium in freiburg, germany, by joseph muenzer, m.d., ph.d., bryson distinguished professor in pediatric genetics, university of north carolina at chapel hill.
DNLI Ratings Summary
DNLI Quant Ranking